Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ENTX
Entera Bio Ltd.
stock NASDAQ

Market Open
May 12, 2025 3:59:47 PM EDT
2.15USD0.000%(0.00)1,351
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-2.15)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
08:31AM EST  Entera Bio Announces EB613 End-Of-Phase 2 Meeting With FDA: FDA Agrees To Phase 3 Twelve Month Study With Lumbar Spine BMD As Primary Endpoint   Benzinga
08:30AM EST  Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with   GlobeNewswire Inc
Nov 10, 2021
08:44AM EST  Entera Bio Reports Nine Months Ended September 30, 2021 EPS $(0.68) Down From $(0.42) YoY   Benzinga
08:39AM EST  Entera Bio 9-month Net Comprehensive Loss $17.1 Mln Or $0.68/Shr Vs $7.7 Mln Or $0.42/Shr Last Year   RTTNews
08:30AM EST  Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis   GlobeNewswire Inc
Oct 28, 2021
08:45AM EDT  Entera Bio Publishes Key Study Describing Its Oral Delivery Technology Platform For Biologic Drugs   Benzinga
08:30AM EDT  Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the Holy Grail of drug development.   GlobeNewswire Inc
Oct 6, 2021
03:47PM EDT  Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data   Benzinga
08:32AM EDT  Entera Bio Presents Phase 2 6-Month Bone MIneral Density Data For Oral PTH Formulation At Late Breaker ASBMR Conference Session; Says Linear Dose Responses Seen; Says Pivotal Phase 3 Registration Study Expected To Commence In 2022   Benzinga
08:30AM EDT  Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613   GlobeNewswire Inc
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 1, 2021
08:30AM EDT  Entera Bio Selected for Late Breaking Oral Presentation of Phase   GlobeNewswire Inc
Aug 23, 2021
11:00AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.   GlobeNewswire Inc
08:30AM EDT  Entera Bio to Present at H.C. Wainwright 23rd Annual Global   GlobeNewswire Inc
Aug 16, 2021
06:41AM EDT  Entera Bio H1 Net Comprehensive Loss $14.6 Mln Or $0.63/Shr Vs Loss $6.1 Mln Or $0.34/Shr Last Year   RTTNews
06:40AM EDT  Entera Bio Q2 EPS $(0.20) Misses $(0.12) Estimate, Sales $109.00K Beat $90.00K Estimate   Benzinga
06:30AM EDT  Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met   GlobeNewswire Inc
04:04AM EDT  Earnings Scheduled For August 16, 2021   Benzinga
Aug 13, 2021
04:30PM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at 06:30am ET.   GlobeNewswire Inc
Aug 2, 2021
08:30AM EDT  The Studys Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo   GlobeNewswire Inc
Jun 28, 2021
03:15PM EDT  Entera Bio to Conduct Conference Call on June 30 to Discuss Phase   GlobeNewswire Inc
Jun 24, 2021
08:35AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Jun. 24, 2021: DKNG, ROKU, UPS, DOCS, ENTX   Benzinga
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
04:56AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 4.55 A.M.)   RTTNews
Jun 23, 2021
02:31PM EDT  Mid-Afternoon Market Update: Patterson Companies Drops On Earnings Miss; Entera Bio Shares Gain   Benzinga
12:14PM EDT  Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide   Benzinga
10:59AM EDT  Mid-Morning Market Update: Markets Rise; IHS Markit Earnings Beat Views   Benzinga
09:58AM EDT  Shares of Entera Bio Ltd. (ENTX) are surging over 66% on Wednesday morning after the biotech company's mid-stage trial of osteoporosis treatment met primary and secondary points.   RTTNews
08:31AM EDT  Entera Bio Reports Topline Phase 2 Bone Mineral Density Data For EB613, Study Met Primary Endpoint   Benzinga
08:30AM EDT  Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613,   GlobeNewswire Inc
Jun 17, 2021
08:07AM EDT  Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European   Benzinga
08:00AM EDT  Oral delivery technology has potential to transform $20 billion injectable biologics market   GlobeNewswire Inc
Jun 16, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021   Benzinga
07:51AM EDT  B. Riley Securities Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $9   Benzinga
May 20, 2021
08:10AM EDT  Entera Bio Q1 EPS $(0.43) Down From $(0.16) YoY, Sales $157.00K Up From $42.00K YoY   Benzinga
08:00AM EDT  Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21   GlobeNewswire Inc
Apr 20, 2021
09:00AM EDT  Entera Bio Says Ron Mayron Has Joined Its Board   RTTNews
08:45AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010, and was Chairman from 2014 to 2016.   GlobeNewswire Inc
Apr 15, 2021
08:35AM EDT  Entera Names Ramesh Ratan CFO   Benzinga
08:30AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Enteras interim U.S. CFO.   GlobeNewswire Inc
Apr 6, 2021
08:30AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled Pharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice at the 31st Annual European Pharma Congress in London on April 28-29, 2021.   GlobeNewswire Inc
Mar 25, 2021
07:30AM EDT  Abeona Therapeutics Announces Appointment of Two New Independent   GlobeNewswire Inc
Mar 22, 2021
10:42AM EDT  Aegis Capital Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $12   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
08:05AM EDT  Entera Bio FY20 EPS $(0.55), Up From $(0.89) YoY   Benzinga
08:00AM EDT  Entera Bio Ltd Announces Operating and Financial Results for the   GlobeNewswire Inc
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
Mar 15, 2021
10:25AM EDT  Mid-Morning Market Update: Markets Edge Higher; Roche To Acquire GenMark Diagnostics In $1.8B Deal   Benzinga
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 12, 2021
12:11PM EST  Mid-Day Market Update: Evoke Pharma Falls Following Q4 Earnings; NLS Pharmaceutics Shares Climb   Benzinga
10:13AM EST  Mid-Morning Market Update: Markets Mixed; Buckle Earnings Top Views   Benzinga
08:16AM EST  Benzinga Pro's Top 5 Stocks To Watch For Friday, Mar. 12, 2021: EXPR, HOFV, VUZI, ENTX, ENG   Benzinga
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
04:15PM EST  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.   GlobeNewswire Inc
02:49PM EST  Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Entera Bio Shares Gain   Benzinga
12:59PM EST  Mid-Day Market Update: Crude Oil Rises Over 2%; Siebert Financial Shares Spike Higher   Benzinga
11:37AM EST  Hearing Maxim Raises Price Target On Entera Bio To $10   Benzinga
10:22AM EST  Mid-Morning Market Update: Markets Open Higher; US Initial Jobless Claims Drop To 712,000   Benzinga
09:24AM EST  Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study   Benzinga
08:32AM EST  Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data; Co. Reports Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data   Benzinga
08:30AM EST  Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21   GlobeNewswire Inc
Mar 4, 2021
08:30AM EST  Entera Bio To Present At The H.C. Wainwright Global Life Sciences   GlobeNewswire Inc
Feb 25, 2021
08:30AM EST  EB612 When Added to Standard of Care Led to a Statistically Significant Decrease inSupplemental Calcium Usage   GlobeNewswire Inc
Feb 8, 2021
08:39AM EST  Entera Bio Says Initiates New Research Program For Oral GLP-2   Benzinga
08:30AM EST  Program Leverages Enteras Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications GLP-2 Analogs Currently Administered Via Daily Injection to Treat Short Bowel Syndrome   GlobeNewswire Inc
Jan 11, 2021
08:35AM EST  Entera Bio Says Strengthened Balance Sheet At Dec. 31, 2020 To ~$8.6M   Benzinga
08:34AM EST  Entera Bio Issues Letter To Shareholders   Benzinga
08:30AM EST  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.   GlobeNewswire Inc
Dec 10, 2020
08:32AM EST  Entera Bio Announces FDA Approval Of IND Application For EB613 An Oral Human Parathyroid Hormone (1-34) For Treatment of Osteoporosis   Benzinga
08:30AM EST  Entera Bio Announces FDA Approval of IND Application for EB613   GlobeNewswire Inc
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 30, 2020
04:06PM EST  Entera Bio Appoints Spiros Jamas as Chief Executive Officer   Benzinga
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
06:35AM EST  Entera Bio Q3 EPS $(0.09) Beats $(0.20) Estimate, Sales $50.00K Down From $60.00K YoY   Benzinga
06:30AM EST  Entera Bio Ltd Announces Third Quarter 2020 Financial Results and   GlobeNewswire Inc
04:24AM EST  Earnings Scheduled For November 19, 2020   Benzinga
Nov 13, 2020
07:30AM EST  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S. financial markets open.   GlobeNewswire Inc
Nov 9, 2020
08:46AM EST  Entera Bio Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Eb613 In Osteoporosis   Benzinga
08:30AM EST  Company Expects to Report Interim 3 Month Biomarker Data for All Enrolled Patients in Q1:21with Final Bone Mineral Density, or BMD, Data Expected in Q2:21   GlobeNewswire Inc
Nov 2, 2020
04:05PM EST  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. Wainwright Annual Israel Conference on Thursday, November 12, 2020 at 8:00 a.m. ET.   GlobeNewswire Inc
Sep 10, 2020
08:30AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference onTuesday, September 15, 2020 at 3:00 p.m. EDT.   GlobeNewswire Inc
Aug 20, 2020
06:36AM EDT  Entera Bio Q2 EPS $(0.17) Down From $(0.12) YoY   Benzinga
06:35AM EDT  Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial Of EB613 In Osteoporosis   Benzinga
06:30AM EDT  6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact onLumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner Company Expects to Complete Patient Enrollment in Q3:20 and Report InterimBiomarker Data from 2.5 mg Dose in Q1:21 with Final Data Expected in Q2:21 Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 20, 2020   Benzinga
Aug 17, 2020
08:30AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S. financial markets open.   GlobeNewswire Inc
Aug 14, 2020
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Aug 10, 2020
09:00AM EDT  Entera Bio Announces Roger Garceau Interim CEO   Benzinga
08:40AM EDT  Entera Bio Appoints Roger Garceau As Interim CEO   RTTNews
08:30AM EDT  Entera Bio Announces Management Changes   GlobeNewswire Inc
Aug 5, 2020
08:30AM EDT  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference onMonday, August 10, 2020at12:30 p.m. EDT.   GlobeNewswire Inc
Jul 22, 2020
04:05PM EDT  Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC